Biosimilars: The Grand Experiment

Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]

Washington Examiner: No, a European-Style Health System Isn’t the Answer

As candidates for the 2020 Democratic nomination present their visions for “Medicare for all,” politicians on both sides of the aisle are increasingly looking to imitate Europe’s health systems to lower the cost of healthcare. But a European system would come at the cost of lower survival rates, longer wait times, and rationing care — […]

Parents’ Flawed Judgement Puts Society at Risk

All but eradicated at the turn of the Century, the Center for Disease Control (CDC) has now confirmed 1,172 cases of measles in 30 states so far this year. The resurgence in case is a growing concern, considering vaccines have long been available. The Governor of Washington State, for instance, declared a state of emergency […]

The Hill: Misleading information on e-cigarettes risks lives

Public health advocates should give consumers the facts about e-cigarettes. By equating the health risks of e-cigarettes and combustible cigarettes and failing to acknowledge the different relative risks of these products, authority figures are doing a disservice to the millions of smokers who may be seeking a safer alternative but are misled into believing there […]

Real Clear Health: Imposing High Taxes on E-cigarettes Misses the Bigger Picture

Despite academic research showing e-cigarettes are 95 percent less harmful than combustible cigarettes, lawmakers and public health “advocates” continue to wage a war on vaping, pushing for higher taxes on e-cigarettes throughout the U.S. If policymakers are serious about curbing the high economic and human cost of smoking, they should not enact high taxes on […]

Coalition Letter Calling on the Senate Not to End the Current Development of Quality Standards for Biologics

July 23, 2019 Dear Chairman Grassley and Ranking Member Wyden, As organizations representing American consumers, seniors, taxpayers, and free-market advocates, we are writing to express concerns over Section 207 of S. 1895, the Lower Health Care Costs Act. Many provisions of the bill would expand consumer choice, save taxpayer money, and lower out-of-pocket costs for […]

THE HILL: Public Quality Standards for Biologic Drugs Promote Transparency and Competition; Don’t Get Rid of Them

A draft of the Lower Health Care Costs Act circulated by the U.S. Senate’s powerful Health, Education, Labor, and Pensions Committee includes a provision that would drastically change how the U.S. develops standards for the strength, quality, and purity of medicines, particularly cutting-edge biologics and biosimilars. Read this op-ed at The Hill to learn why […]